Flagship · Bulletin

Macro rationale

Signal crossover, not a turn. Genuinely risk-on: VIX 14.9 at -19.9% vs its 200d SMA, HY OAS inside its 90d SMA, 2s10s +0.38 un-inverted. Offsetting: QQQ +11.4% above its 200d fires the extension escalator, weekly RSIs are mid-band (61/67), and the concentration escalator is live with AI-load look-through at 30.81% of NAV — over its §2 30% early-warning trigger. That combination is NEUTRAL, and the cash band stays NEUTRAL base 5-15% with the escalated ceiling at 30% (extension + concentration both active, cited). Every named funder underneath the book is intact: ~$725B 2026 hyperscaler capex, TSMC CoWoS booked out through 2026 and HBM sold out across the three-supplier oligopoly, term U3O8 $94-95.50/lb, copper at all-time highs above $6.50/lb, FY2026 defense enacted at $839.2B (P.L. 119-75), and a wide-open biotech capital window (18 H1 IPOs, $96B of M&A). So this run is a mechanical concentration cure, not a de-risking: the §2 AI-load cap is a policy rule, and it binds on the two weakest AI-correlated energy names rather than on the compute franchises, which are already sized at 1.3-5.8% after four consecutive rounds of cap trims. Cash rises only by the un-deployable trim proceeds (stale_policy blocks redeployment) and sits inside the escalated ceiling on the extension + concentration signals.

Thesis

Scope-locked, event-driven concentration cure — not a flow break. The §2 AI-load look-through fired at 30.81%, over its 30% cap, so the mandate is a mechanical trim toward diversification. Two tickets, both inside the scoped list, both on the weakest-scored AI-correlated ENERGY names rather than on the compute franchises (which have already absorbed four consecutive rounds of cap trims and now sit at 1.3-5.8%). (1) CCJ -2.06pp to 2.00%: the score conflict I flagged twice is now resolved the wrong way — briefer AND paper book both print 45 with verdict=broken, on a Q2 revenue -7% / EPS miss. The uranium funder (term U3O8 $94-95.50, DOE $17.5B AP1000, Kazatomprom cut) is intact, so this is a right-size to a residual, and SCCO+NEM carry the §5.3 hedge floor without it. (2) GEV -2.00pp to 2.92%: wind revenue -10% / orders -40% with score 61 one leg above the floor; the $176B backlog and turbines-sold-out-through-2030 gas thesis is unbroken, so again a right-size, not an exit — and this is the same ticket that was refused last run. Together these take entry-basis AI-load from 32.02% to 27.96%, under the trigger. Everything else is re-affirmed verbatim at prior entry weight, delta 0 — including MU (two haiku high-flags on memory pricing, but score 86 and the SCA book intact: watch, do not churn) and locked LUNR. Mid-cap sleeve: DRS, LMT, ORCL and AMKR were reviewed; none exceeds an incumbent by 5+ points, and stale_policy blocks opens anyway. GD and VEEV are carried forward at the

Reflection

Concentration mechanics again, not deterioration: AI-load 30.81% over cap while every funder — $725B capex, HBM sold out, U3O8 $94+, copper ATH, $839B defense — holds.

The CCJ ambiguity finally resolved: briefer and paper book now agree at 45/broken, so the 'expensive kind of ambiguity' I journaled twice was real and I under-cut it last run. Second: MU is the first compute name where the FUNDER itself wobbled rather than the score — SK Hynix/Samsung peak-price undershoot is a genuine pricing signal, and haiku high-flags run 78% at 7d. Score 86 says hold; I am watching the SCA book, not the tape. Third, the structural defect persists: the book is 16 names against an 18-position floor under stale_policy, so I must list opens I know will be refused. That mechan

Positions (16)

• MUMicron Technologycompute

  hold3.36%88
  flow softeningconf

  Funder

  Only US-domiciled leading-edge DRAM/HBM maker: 84.6% gross margin, FCF positive, and genuine supply discipline after two decades of cycle abuse. Named flow: 16 multi-year Strategic Customer Agreements (~$100B contracted), the June Anthropic multi-year supply agreement, and 2026 HBM production sold out across the three-supplier oligopoly against the ~$725B hyperscaler capex line.

  Unwind

  DRAM/NAND spot collapse or HBM oversupply breaking the shortage thesis; hyperscaler capex cut; erosion of the 16-SCA contract book; CXMT Beijing capacity landing at scale. SK Hynix/Samsung signalling that peak DRAM pricing undershoots is the live warning — two quarters of falling HBM bookings would break it.

  Catalyst

  Next MU earnings print — HBM4 bookings trajectory and whether contracted SCA pricing holds against the SK Hynix/Samsung peak-price undershoot.

  Scenarios · 12mo targets

  $340.00 base

  $420.00 bull — HBM4 qualification at NVIDIA/AMD plus SCA repricing keeps the memory cycle tight through 2027; MU compounds the AI-memory share gain toward 25%.

  $200.00 bear — Peak DRAM pricing undershoots, SK Hynix adds capacity and CXMT floods commodity DRAM; margins mean-revert hard off an 84.6% gross-margin peak.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold5.07%86
  flow steadyconf

  Funder

  World-leading foundry with an effective monopoly at <=3nm — every meaningful AI accelerator routes through it. >50% GM, prodigious FCF, famously disciplined capex, ~73% foundry share and ~90% of advanced AI chip production. Named flow: $100B capex commitment, CHIPS $6.6B Arizona disbursement, CoWoS booked out through 2026 (75K->130K wpm), CEO demand visibility into 2029-30.

  Unwind

  Gross margin sustained <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan-strait event Arizona capacity cannot offset; hyperscaler capex cut breaking the 2027 AI-capex forecast. Druckenmiller's 9% Q1 sale is monitored, not a break.

  Catalyst

  Monthly revenue prints and the next quarterly guide — CoWoS capacity adds and 2027 pricing are the confirmations.

  Scenarios · 12mo targets

  $400.00 base

  $480.00 bull — 2027 price hikes stick, N2 ramps on schedule and CoWoS expansion converts the booked backlog; foundry share pushes past 75% with margins above 55%.

  $250.00 bear — A 2027 hyperscaler capex deceleration hits leading-edge utilization, or a Taiwan-strait risk premium re-rates the multiple regardless of earnings.

• NVDANVIDIAcompute

  hold3.14%74
  flow steadyconf

  Funder

  AI-accelerator franchise with the CUDA software moat — ~74.9% gross margin, fortress balance sheet, developer lock-in no ASIC rival has replicated. Named flow: ~$725B 2026 hyperscaler capex anchored on Blackwell/Rubin (MSFT $190B, AMZN $200B, GOOGL $180-190B, META $125-145B), Stargate $500B JV, and neocloud demand (Nebius $27B GPU deal).

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters; hyperscaler in-sourcing plus AMD wins pushing competitor share toward the 25% TAM invalidation line; a hyperscaler capex guide-down; export-control tightening that removes a material share of demand.

  Catalyst

  Next earnings — data-center revenue growth rate and Rubin ramp commentary against the ASIC in-sourcing narrative.

  Scenarios · 12mo targets

  $250.00 base

  $320.00 bull — Rubin ramps into an inference build-out that keeps DC growth above 40%; CUDA lock-in holds ASIC share below 20% and margins stay near 75%.

  $150.00 bear — The capex-to-revenue gap (~$725B spend vs <$35B pure-play AI vendor revenue) closes the wrong way in 2027 and the $5.3T valuation de-rates on decelerating DC growth.

• ASMLASML Holdingcompute

  hold2.57%62
  flow softeningconf

  Funder

  EUV / High-NA monopoly — the single most irreplaceable tool in advanced semis, no commercial-scale alternative at 2nm, multi-year backlog, ~50% gross margin. Named flow: Intel's July 2026 Ultra 3 design win confirming High-NA deployment, the TSMC/Samsung/Intel 2025-27 EUV orderbook, Norway GPFG holding with Coatue/Third Point added in Q1.

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; a Dutch/US export-control tightening removing a material share of the orderbook; a credible non-EUV patterning path at 2nm. The live erosion is China DUV: state-backed domestic DUV systems against China revenue already 41%->16%.

  Catalyst

  Next quarterly bookings print — EUV/High-NA book-to-bill and China DUV share commentary.

  Scenarios · 12mo targets

  $1,300.00 base

  $1,600.00 bull — High-NA orders convert as Intel/TSMC/Samsung move to 14A/N2; the EUV monopoly reprices on a 2027 orderbook that China DUV cannot touch.

  $850.00 bear — Chinese domestic DUV takes the remaining 16% China revenue and a litho digestion year drops book-to-bill below 0.7 at a 37x forward multiple.

• AVGOBroadcomcompute

  hold2.54%63
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~70% share) plus the VMware infrastructure-software moat — huge FCF, $7B+ annual buyback, serial dividend grower, one of the best capital-allocation records in semis under Hock Tan. Named flow: Alphabet TPU multi-generation program running to 2031, META MTIA, Anthropic 3.5GW ASIC contracts, and Druckenmiller's new ~2% stake disclosed this month.

  Unwind

  AI custom-chip revenue stalling below a $25B annual run-rate; full hyperscaler in-sourcing displacing the ASIC design franchise; VMware renewal churn breaking the software annuity; a leverage or buyback pause signalling balance-sheet stress.

  Catalyst

  Next earnings — AI semiconductor revenue run-rate and custom-ASIC bookings vs the $25B invalidation line.

  Scenarios · 12mo targets

  $500.00 base

  $620.00 bull — Alphabet external TPU sales plus Anthropic's 3.5GW ramp push AI revenue well past $30B; VMware annuity holds and the buyback compounds share count down.

  $320.00 bear — Hyperscalers in-source design work, AI bookings stall below $25B and VMware churn shows up in software renewals.

• ANETArista Networkscompute

  hold2.26%65
  flow acceleratingconf

  Funder

  Durable hyperscaler-networking franchise and consistent share-gainer since 2004 — ~62% gross margin, net cash, no debt, and the single-image EOS software moat that keeps switching costs high under Jayshree Ullal. Named flow: first $3B quarter with 37.7% YoY growth, FY2026 guide raised to $12.6B (~40%), the new 1.6 Tbps AI fabric platform and at least one new named hyperscaler win; Microsoft and Me

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; Spectrum-X or whitebox displacing EOS in a named hyperscaler footprint; gross margin breaking below ~60%.

  Catalyst

  Next quarter — whether the raised ~40% FY2026 growth guide holds and the 1.6 Tbps platform books a second hyperscaler.

  Scenarios · 12mo targets

  $220.00 base

  $270.00 bull — AI-cluster Ethernet keeps taking share from InfiniBand; the 1.6 Tbps fabric adds hyperscaler footprints and growth stays near 40% on 62% margins.

  $140.00 bear — Spectrum-X or whitebox displaces EOS at one large hyperscaler while a 48x forward multiple leaves no room for decelerating growth.

• CCJCamecoenergy

  trim2.20%-2.06pp42
  flow softeningconf

  Funder

  Tier-1 Saskatchewan uranium franchise (McArthur River/Cigar Lake) plus the 49% Westinghouse JV with Brookfield — irreplaceable permitted low-cost tonnes in a stable jurisdiction. Named flow still intact: term U3O8 $94-95.50/lb vs a legacy contract book near $60, Kazatomprom's 8Mlb output cut, the DOE $17.5B AP1000 loan commitment and the Trump-Saudi civil-nuclear deal.

  Unwind

  Uranium spot/term price collapse; contract-book erosion or failure to reprice legacy contracts upward; a reactor-build program cancellation; sustained Westinghouse earnings drag. The active break is fundamental: score 45 with a Q2 revenue -7% and EPS miss — a third weak print takes the slot to zero.

  Catalyst

  Q3 print — Westinghouse contribution and whether legacy contracts reprice toward the $94+ term market.

  Scenarios · 12mo targets

  $90.00 base

  $115.00 bull — Legacy contracts roll into the $94+ term market while Westinghouse AP1000 orders convert off the DOE commitment; uranium supply deficit persists.

  $55.00 bear — Westinghouse keeps dragging earnings, Q3 misses again and the term price rolls over — score stays sub-50 and the slot closes.

• GEVGE Vernovaenergy

  trim3.21%-2.00pp61
  flow steadyconf

  Funder

  Gas-turbine and grid franchise with genuine pricing power — record ~$176B backlog, turbines sold out through 2030, 10-20% price realization on new orders, quadrupled FCF, and a three-player global oligopoly. Named flow: Q2 orders +88% and revenue +22% with raised FY guidance, Norway GPFG added post-spin, Oracle/Alphabet datacenter capex pull-through, the DOE Tier-1 $800M BWRX-300 award at Clinch R

  Unwind

  Gas-turbine backlog cancellation or a hyperscaler power-capex cut; wind losses widening enough to consume gas-segment profit; EV/EBITDA breaching the ~25x exit line with orders decelerating.

  Catalyst

  Q3 print — gas/electrification order growth and whether wind losses (revenue -10%, orders -40%) stop widening.

  Scenarios · 12mo targets

  $750.00 base

  $950.00 bull — Datacenter power demand keeps gas orders compounding off the $176B backlog with 10-20% price realization; wind is ring-fenced and grid margins inflect.

  $450.00 bear — Wind losses widen enough to eat gas-segment profit, or a hyperscaler power-capex pause stalls turbine bookings at a 25x+ multiple.

• SCCOSouthern Copperenergy

  hold8.79%67
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost major copper producer with the industry's largest reserve base, ~68% gross margin, FCF positive and a large dividend; Grupo Mexico control enforces capital discipline. Named flow: copper at all-time highs above $6.50/lb vs a $5 entry trigger, a ~320kt 2026 supply deficit, AI/datacenter demand ~30% of new copper demand by 2030 (BloombergNEF), and BHP data sh

  Unwind

  Copper price collapse breaking the deficit thesis; Tia Maria / Los Chancas permitting reversal; a dividend cut signalling balance-sheet stress.

  Catalyst

  Tia Maria / Los Chancas permitting milestones and the next quarterly dividend declaration against copper spot.

  Scenarios · 12mo targets

  $165.00 base

  $200.00 bull — The 320kt deficit persists as datacenter and grid copper demand compounds; Tia Maria permits clear and the dividend steps up on record margins.

  $110.00 bear — A demand shock (Hormuz-driven energy spike into global slowdown) breaks copper off its ATH and Peruvian permitting reverses.

• NEMNewmont Corporationenergy

  hold8.26%84
  flow steadyconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer with tier-1 long-life assets, strong post-Newcrest FCF and dividend, and visibly improving cost discipline after the divestiture program. Named flow: sustained central-bank gold accumulation as reserve diversification, a restrictive-real-rate / sticky-core-PCE backdrop (core 3.4%) keeping the stagflation hedge live, and the TD Cowen upgrade to B

  Unwind

  Cost overruns or mine disappointments breaking FCF and the dividend; durable disinflation plus a real-rate surge removing the stagflation-hedge rationale; a peace-and-easing regime that ends the central-bank bid.

  Catalyst

  Next quarterly AISC print and the pace of central-bank gold purchases; any Fed pivot to durable disinflation.

  Scenarios · 12mo targets

  $130.00 base

  $160.00 bull — Central-bank buying plus a hawkish-hold-into-stagflation tape keeps gold bid while post-Newcrest AISC falls; FCF funds a bigger dividend and buyback.

  $90.00 bear — Durable disinflation and a real-rate surge unwind the gold trade while cost overruns at tier-1 assets squeeze the dividend.

• KTOSKratos Defensedefense

  hold8.92%64
  flow steadyconf

  Funder

  Tactical drones (XQ-58A Valkyrie), hypersonics and turbine engines — a scarce non-prime supplier of attritable airframes with ~22% gross margin. Named flow intact: DoD MACH-TB 2.0 IDIQ prime ($1.45B ceiling), Project Helios $68.3M single-award, USMC Valkyrie MUX mods, the Pentagon's $1.1B drone-dominance program, a $50M hypersonic facility completed ahead of schedule, and FY2026 defense enacted at

  Unwind

  Backlog or contract cancellations; margin failing to inflect through the drone ramp with FCF staying negative; a DoD unmanned-systems funding cut, or FY2027 appropriations slipping past October 1 into a CR with new-start prohibitions.

  Catalyst

  FY2027 appropriations progress ahead of October 1, plus the next earnings print on drone-segment margin inflection.

  Scenarios · 12mo targets

  $95.00 base

  $125.00 bull — Valkyrie and MACH-TB task orders convert at scale, drone margins inflect and FCF turns positive as the $42.8B military-drone market compounds.

  $55.00 bear — FY2027 slips into a CR that blocks new starts, task-order conversion stalls and FCF stays negative through the ramp.

• HEIHEICOdefense

  hold10.23%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder and a textbook 20-30 year franchise — the Mendelson family has owned and run it since 1957, compounding FCF at 20%+ with a disciplined serial-acquisition model (~$1B/yr of bolt-ons). Named flow: record Q2 (net income +49% YoY, sales $1.375B +25%, ETG operating income +56%), NDAA mandatory funding plus the commercial-aerospace MRO cycle, and Berkshire's holding u

  Unwind

  Organic growth decelerating below 6% WITH margin compression; forward P/E sustained above 50x with growth deceleration confirmed (valuation alone is not the trigger); a leveraged acquisition that breaks the capital-allocation record.

  Catalyst

  Next quarterly print — FSG/ETG organic growth and whether the ~54x forward multiple is still backed by 20%+ FCF growth.

  Scenarios · 12mo targets

  $430.00 base

  $520.00 bull — MRO demand and ETG defense-electronics momentum keep organic growth in the teens while bolt-ons add another leg; the family model compounds FCF at 20%+.

  $290.00 bear — Organic growth decelerates below 6% with margin compression while a ~54x forward multiple de-rates — the named valuation guardrail.

• LLYEli Lillybiology

  hold6.81%73
  flow acceleratingconf

  Funder

  Premier pharma compounder — the Mounjaro/Zepbound GLP-1 franchise (~60% US share) plus oral orforglipron (Foundayo, FDA-approved) and retatrutide in Phase 3, on ~86% gross margin with strong FCF and a $27B manufacturing build. Named flow: Q2 revenue +48% YoY with Mounjaro $9.9B and Zepbound $4.9B, retatrutide FDA filing dated Q1 2027 on 28.3% weight loss, and the July 31 Section 232 pharma tariff

  Unwind

  Tirzepatide US script share falling >5pts to Novo over two quarters; retatrutide Phase 3 disappointing on safety or durability; IRA/MFP negotiation reaching the GLP-1 franchise on terms that break pricing; a manufacturing-capacity stumble.

  Catalyst

  Retatrutide FDA submission (Q1 2027) and the next quarterly script-share read vs Novo and Pfizer's berobenatide.

  Scenarios · 12mo targets

  $1,250.00 base

  $1,500.00 bull — Retatrutide files on 28.3% weight loss and orforglipron scales the oral market; GLP-1 revenue compounds past $60B with the tariff favoring US plants.

  $800.00 bear — IRA/MFP selection reaches the incretin franchise or retatrutide disappoints on safety, and script share leaks to Novo/Pfizer.

• VRTXVertex Pharmaceuticalsbiology

  hold4.55%82
  flow acceleratingconf

  Funder

  Durable biology compounder: the cystic-fibrosis monopoly (Trikafta/Alyftrek) is a self-funding cash engine with ~85% gross margin, no meaningful competition, and a fortress net-cash balance sheet. Named flow: the $10B Crinetics acquisition (July 30) deploying that FCF into endocrinology, Casgevy commercializing across 12+ jurisdictions with the Medicare cell-therapy access model, and the suzetrigi

  Unwind

  The CF franchise eroding faster than non-CF revenue can replace it; the Crinetics integration destroying value or pushing forward P/E toward the 30x invalidation line; a suzetrigine launch failure or Casgevy uptake stall.

  Catalyst

  Suzetrigine launch metrics and Casgevy uptake in the next print; Crinetics integration milestones.

  Scenarios · 12mo targets

  $560.00 base

  $660.00 bull — Journavx scales into the non-opioid pain market and Crinetics adds an endocrinology leg; CF cash flow funds diversification without dilution.

  $380.00 bear — Non-CF launches underdeliver while CF matures, and the $10B Crinetics deal proves value-destructive at a stretched multiple.

• ARGXargenxbiology

  hold4.24%70
  flow steadyconf

  Funder

  argenx — the Vyvgart/Vyvgart Hytrulo (efgartigimod) FcRn autoimmune franchise: a first-mover platform with a decade of indication runway, self-funded, commercial-stage, high-margin and net cash. Named flow: FDA expansion of gMG approval to all serotypes including seronegative (~18% TAM lift), positive efgartigimod data in myositis and Sjogren's, Sanofi's riliprubart Phase 3 CIDP failure clearing t

  Unwind

  Vyvgart revenue growth stalling; a pipeline indication failure in myositis or Sjogren's; a competitor FcRn entrant taking measurable share; the Forte deal turning into an integration/cash drain.

  Catalyst

  Myositis / Sjogren's registrational readouts and the next Vyvgart revenue print; Forte tender completion.

  Scenarios · 12mo targets

  $850.00 base

  $1,000.00 bull — Myositis and Sjogren's convert into label expansions on a franchise already compounding; Sanofi's CIDP failure leaves FcRn share uncontested toward $16B TAM.

  $560.00 bear — A pipeline indication misses and a rival FcRn entrant takes share, stalling Vyvgart growth while Forte adds spend without a pipeline win.

• LUNRcompute

  hold1.10%54
  flow softeningconf

  Funder

  Intuitive Machines — named government backlog is the whole thesis: NASA Near Space Network IDIQ ($4.82B ceiling, active), a $148.3M firm-fixed-price CLPS task order, the Space Force Andromeda IDIQ ($6.2B ceiling), and $1.1B contracted backlog against ~$1B FY2026 revenue guidance with a stated 2027 profitability path.

  Unwind

  Backlog conversion stalling; the profitability pathway breaking; a NASA CLPS or SDA program funding cut; further insider selling on top of the CTO's $3.3M June sale. Score is already 55 (below the 60 floor) — a failed backlog-to-revenue conversion closes the slot.

  Catalyst

  Next quarterly print — backlog-to-revenue conversion against the $1B FY2026 guide and the 2027 profitability path.

  Scenarios · 12mo targets

  $12.00 base

  $18.00 bull — CLPS and Near Space Network task orders convert on schedule, FY2026 revenue lands near $1B and the 2027 profitability path is confirmed.

  $4.00 bear — Backlog conversion slips, cash burn forces dilution, and a NASA/SDA funding reallocation post-SpaceX-IPO removes the government bid.

Warnings

• stale_policy guard: GD open → hold (delta zeroed)
• stale_policy guard: VEEV open → hold (delta zeroed)
• §5.4 dry-powder: cash_pct 17.41% above base band top 15% allowed by §3b unfilled-sleeve headroom (+17.5pp, eff top 32.5%)
• cash_band: final cash 22.75% above neutral base band top 15% (escalator active: extension, concentration; §3b dry-powder headroom +17.5pp (unfilled opportunistic sleeve → cash)) (§5.4)
• cash_reconcile: executed cash 24.97% sits 5.62pp ABOVE the intent baseline — committed weights re-anchored 5.62pp down toward live across NEM, SCCO, LLY, VRTX (§5.4 commit honesty; no mechanical buys — redeployment stays an Opus decision)

Conviction-lock actions

No conviction-lock refusals or overrides this run.

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.